Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-11-16

Clinical Trial Update: Nicotinamide Riboside in Systolic Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating nicotinamide riboside for systolic heart failure; study completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nicotinamide Riboside (nicotinamide riboside)

Snippet

Sponsor: University of Washington | Conditions: Heart Failure, Systolic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-16